Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Offer Update

7 Aug 2007 17:41

Babcock International Group PLC07 August 2007 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO ORFROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THERELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE PRESS ANNOUNCEMENT 7 August 2007 BABCOCK INTERNATIONAL GROUP PLC ("BABCOCK") FINAL CASH OFFER FOR INTERNATIONALNUCLEAR SOLUTIONS PLC ("INS" OR THE "COMPANY") OFFER UPDATE On 9 July 2007, Babcock announced that the Final Cash Offer had becomeunconditional in all respects. As at 3.00 p.m. (London time) on 7 August 2007, Babcock has acquired or hasreceived valid acceptances in respect of a total of 37,128,350 INS Shares,representing approximately 58.9 per cent. of the existing issued share capitalof INS. Of this total: - Babcock owns (other than pursuant to valid acceptances of the Final Cash Offer) 27,954,131 INS Shares, representing approximately 44.3 per cent. of the existing issued share capital of INS; and - Babcock has received valid acceptances for 9,174,219 INS Shares representing approximately 14.6 per cent. of the existing issued share capital of INS (including acceptances pursuant to irrevocable undertakings to accept the Final Cash Offer in respect of a total of 253,904 INS Shares, representing approximately 0.4 per cent. of the existing issued share capital of INS). Extension of the Final Cash Offer The Board of Babcock announces that the Final Cash Offer has been extended andwill remain open for acceptance for a further 14 days, until 3.00 p.m. on21 August 2007. Procedure for acceptance INS Shareholders who have not yet accepted the Final Cash Offer are urged to doso as soon as possible and in any event no later than 3.00 p.m. on 21 August2007. The procedure for acceptance is set out in paragraph 18 of Part 2 of theOffer Document. Forms of Acceptance not yet returned should be completed and returned inaccordance with the instructions set out in the Offer Document and in the Formof Acceptance so as to be received as soon as possible and in any event no laterthan 3.00 p.m. on 21 August 2007. If INS Shares are held in CREST acceptance should be made electronically so thatthe TTE instruction settles as soon as possible and in any event no later than3.00 p.m. on 21 August 2007. Settlement for INS Shareholders who have validly accepted the Final Cash Offerwill be despatched within 14 days of the relevant acceptance by first class post(in the case of INS Shares held in certificated form) or credited to therelevant CREST account (in the case of INS Shares held in uncertificated form).Settlement of the consideration in respect of further acceptances of the FinalCash Offer, which are valid and complete in all respects, will be despatchedwithin 14 days of receipt. Terms defined in the Offer Document dated 19 June 2007 shall have the samemeaning in this announcement. Enquiries: Babcock Telephone: +44 (0) 20 7291 5000Gordon CampbellPeter RogersBill Tame Hawkpoint (financial adviser to Babcock) Telephone: +44 (0) 20 7665 4500Chris Robinson JPMorgan Cazenove (broker to Babcock) Telephone: +44 (0) 20 7588 2828Dermot McKechnie Financial Dynamics (Babcock PR enquiries) Telephone: +44 (0) 20 7269 7121Susanne Walker The release, publication or distribution of this announcement to persons who arenot resident in the United Kingdom may be affected by the laws of the relevantjurisdictions in which they are located. Persons who are not resident in theUnited Kingdom should inform themselves of, and observe, any applicablerequirements. Any failure to comply with such applicable requirements mayconstitute a violation of the securities laws of any such jurisdictions. Hawkpoint, which is authorised and regulated in the United Kingdom by theFinancial Services Authority, is acting exclusively for Babcock and no one elsein connection with the Final Cash Offer and will not be responsible to anyoneother than Babcock for providing the protections afforded to clients ofHawkpoint nor for providing advice in relation to the Final Cash Offer, thecontent of this announcement or any matter referred to herein. JPMorgan Cazenove, which is authorised and regulated in the United Kingdom bythe Financial Services Authority, is acting exclusively for Babcock and no oneelse in connection with the Final Cash Offer and will not be responsible toanyone other than Babcock for providing the protections afforded to clients ofJPMorgan Cazenove nor for providing advice in relation to the Final Cash Offer,the content of this announcement or any matter referred to herein. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th May 20237:00 amRNSTransfer of ToxHub Platform and launch of Centrus®
11th May 20233:26 pmRNSHolding(s) in Company
11th May 20237:00 amRNSUS Government Contract Award
4th May 20235:07 pmRNSHolding(s) in Company
3rd May 20237:00 amRNSNotice of Results and Investor Presentation
2nd May 20234:13 pmRNSExercise of Options, Issue of Equity & TVR
14th Apr 20234:38 pmRNSHolding(s) in Company
13th Mar 20237:30 amRNSNo Exposure to Silicon Valley Bank
31st Jan 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSAppointment of Independent Non-Executive Director
5th Jan 20237:00 amRNSExercise of Options, Director/PDMR Dealing & TVR
22nd Dec 20227:00 amRNSContract Extension with Leading CRO
30th Nov 20225:48 pmRNSHolding(s) in Company
12th Oct 20227:00 amRNSExercise of Options, Issue of Equity and TVR
27th Sep 20227:01 amRNSHalf-year Report
27th Sep 20227:00 amRNSSettlement of Historical Licence Dispute
13th Sep 20227:00 amRNSNotice of Results and Investor Presentation
9th Sep 20223:49 pmRNSHolding(s) in Company
2nd Sep 20227:00 amRNS$12m five-year agreement with Leading CRO
4th Aug 20227:00 amRNSHalf Year Trading Update
29th Jun 20225:03 pmRNSHolding(s) in Company
9th Jun 20224:01 pmRNSResult of AGM
20th May 20224:31 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of AGM & Posting of Annual Report
3rd May 202212:00 pmRNSHolding(s) in Company
3rd May 20227:00 amRNSEuropean Medicines Agency Research Grant
26th Apr 20224:40 pmRNSSecond Price Monitoring Extn
26th Apr 20224:35 pmRNSPrice Monitoring Extension
26th Apr 202210:15 amRNSEarn Outs and Deferred Payments
26th Apr 20229:54 amRNSFinal Results
26th Apr 20227:00 amRNSAnnouncement re: full year results
20th Apr 20229:05 amRNSNotice of Results & Investor Presentation
15th Mar 20221:49 pmRNSGrant of PDMR Options
14th Mar 20225:29 pmRNSExercise of Options, Issue of Equity and TVR
14th Mar 202211:22 amRNSHolding(s) in Company
22nd Feb 202210:15 amRNSHolding(s) in Company
4th Feb 20228:08 amRNSDirector/PDMR Shareholding
26th Jan 20227:00 amRNSTrading Update
11th Jan 20227:00 amRNSAppointment of Joint Broker
21st Dec 20217:00 amRNSH2 China Market Update
13th Dec 20214:55 pmRNSHolding(s) in Company
22nd Nov 20212:33 pmRNSHolding(s) in Company
22nd Nov 20217:00 amRNSNew In Silico Software Release
11th Oct 20213:15 pmRNSDirector/PDMR Shareholding
29th Sep 202110:34 amRNSHolding(s) in Company
29th Sep 20217:00 amRNSDirectorate Change
28th Sep 20217:00 amRNSGrant of PDMR Options
27th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSNotice of Results and Investor Presentation
14th Sep 20217:00 amRNSExercise of Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.